Aldeyra Therapeutics, Inc. (ALDX) — Institutional Holders, Q2 2026 (page 2)
108 institutional investment managers reported a ALDX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $77.8M. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 101 to 108. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
ALDX 13F holders ranked 101–108 of 108
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 101 | CITIGROUP#101 · 327 sh | 327 | $697.00 | 0.00% | -89.5% |
| 102 | GAMMA Investing#102 · 320 sh | 320 | $682.00 | — | -71.4% |
| 103 | True Wealth Design#103 · 312 sh | 312 | $665.00 | — | +97.5% |
| 104 | Truvestments Capital#104 · 265 sh | 265 | $564.00 | <0.01% | 0.0% |
| 105 | SJS Investment Consulting#105 · 190 sh | 190 | $405.00 | — | -33.1% |
| 106 | NISA INVESTMENT ADVISORS#106 · 184 sh | 184 | $392.00 | — | -96.0% |
| 107 | HighMark Wealth Management#107 · 155 sh | 155 | $330.00 | <0.01% | 0.0% |
| 108 | TD Waterhouse Canada#108 · 15 sh | 15 | $36.00 | — | 0.0% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.